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The addition of enteral to 
parenteral antimicrobials 
may prolong antibiotic era
ABSTRACT
Resistance to parenteral antimicrobials generally occurs within two years after introduction into general use. The site where 
de novo resistance develops has been acknowledged to be the gut. Overgrowth of abnormal flora, defined as 105 potential 
pathogens per g of faeces is a risk factor for resistance following increased spontaneous mutation leading to polyclonality 
and antimicrobial resistance. As parenteral antimicrobials generally fail to eradicate the abnormal carrier state in overgrowth
concentrations due to sub-lethal concentrations in bile and mucus the enteral antimicrobials polymyxin/tobramycin aiming 
at converting the abnormal carrier state into normal carriage, are the essential component of selective decontamination 
of the digestive tract (SDD), because they eradicate carriage and overgrowth including resistant mutants, maintaining the 
usefulness of parenteral antimicrobials.
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Introduction
Underlying disease determines abnor-
mal carriage, and the abnormal carrier 
state, in particular of the gut, is the main 
risk factor for the emergence of anti-
microbial resistance. (1) For example, 
only diseased individuals carry potenti-
ally pathogenic micro-organisms (PPM) 
such as Pseudomonas aeruginosa in 
overgrowth concentrations, ie. 105 
abnormal bacteria per g of faeces. 
Intravenous ceftazidime induces incre-
ased spontaneous mutation, polyclo-
nality and antibiotic resistance. (2)
Selective decontamination of the dige-
stive tract (SDD) aims to convert the 
abnormal carrier state in overgrowth 
concentrations into normal carriage, 
therefore preventing the emergence of 
antimicrobial resistance. (3)
The many years, over 20, of clinical 
SDD research yielding 57 randomised 
controlled trials (RCTs) demonstrated 
an intriguing finding that SDD does not 
increase the problem of antimicrobial 
resistance but reduces the problem. (4)
Two (5,6) of the 57 RCTs, report an 
increase in resistance. Interestingly, 
the endpoint was the number of resi-
stant isolates, not patients, in these 
two RCTs.
Three RCTs evaluated the impact of 
SDD on the number of patients who 
carried antibiotic resistant aerobic 
Gram-negative bacilli (AGNB). (7-9) 
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A Klebsiella pneumoniae producing 
extended-spectrum beta-lactamase 
(ESBL) was endemic in a French hos-
pital (7): carriage and infection rates 
were 19.6% and 9%, respectively. Once 
enteral antimicrobials were added to 
the parenteral, there was a significant 
reduction in both carriage and infection 
(19.6% versus 1%; 9% versus 0%). (7) 
A Dutch mono-centre RCT including 
1,000 patients reports that carriage of 
AGNB resistant to imipenem, ceftazi-
dime, ciprofloxacin, tobramycin and 
polymyxins occurred in 16% of patients 
receiving parenteral and enteral antimi-
crobials, compared to 26% of control 
patients receiving only parenteral anti-
ciotics with a relative risk of 0.6 (95% CI 
0.5-0.8). (8)
The largest multi-centre RCT to date, 
also from the Netherlands, includes 
6,000 patients, and the proportion of 
patients with Gram-negative bacteria in 
rectal swabs that were not susceptible 
to the marker antibiotics was lower with 
SDD than with standard care or selec-
tive oropharyngeal decontamination 
(SOD), a modified SDD protocol wit-
hout the gut component. For example, 
carriage of multi-resistant P.aeruginosa 
was 0.4% in SDD versus 0.8% in SOD 
and 1.3% in the group receiving stan-
dard care (p<0.005). (9)
The traditional approach is based on 
two pillars, restriction of parenteral anti-
biotics and transmission control using 
hand washing and isolation.
Restriction of solely paren-
teral antimicrobials
There is evidence relating antimicrobi-
al usage to emerging resistance. (10) 
Generally, carriage in the throat and gut, 
and colonisation of internal organs by 
PPM, are not treated. Only infection is 
treated (parenterally) to limit the use of 
systemic antibiotics. Despite widespre-
ad attempts to limit the use of systemic 
antibiotics, over 70% of all patients who 
stay over three days on the intensive 
care unit (ICU) will receive them. (11) 
There are two approaches to controlling 
antibiotic usage. These include increa-
sing the specificity of the diagnosis of 
pneumonia, 30% of all infections, by 
invasive techniques, and scheduled 
changes of antibiotic classes. 
The ‘pneumonia’ rate is halved using 
invasive strategies compared with 
non-invasive methods. (12) Two ran-
domised trials have demonstrated that 
diagnosing pneumonia less frequently 
in this fashion is not associated with a 
reduction in mortality. (13,14) A French 
randomised trial of 413 patients com-
pared 204 patients managed invasively 
with protected brush specimens with 
209 patients managed non-invasively 
with tracheal aspirates. (13) They fai-
led to show any survival benefit at 28 
days (30.9% versus 28.8%, p = 0.10) 
using restrictive antibiotic prescribing 
policies. A Spanish randomised trial 
of 77 patients, comparing an invasive 
diagnostic approach (n = 38), found 
that the 30 day outcome of pneumonia 
was not influenced (38% versus 46%, 
p = 0.46) by the techniques used for 
microbial investigation. (14) Additio-
nally, both trials evaluated the emer-
gence of antimicrobial resistance as 
a secondary endpoint. In the French 
trial the proportions of resistant isolates 
obtained from lower airway secretions 
were similar in both invasive (61.3%) 
and non-invasive (59.8%) groups, des-
pite significantly less use of antibiotics 
in the invasive group. The Spanish trial 
reported identical high isolation rates 
of 58.3% of resistant bacteria, methi-
cillin-resistant Staphylococcus aureus 
(MRSA) and Pseudomonas aeruginosa 
in both groups.
Strategies that recommend manipula-
ting in-hospital antibiotic use have been 
suggested, in order to reduce possible 
emergence of resistance in critically ill 
patients. One such strategy is to sche-
dule a rotation of antibiotics. This stra-
tegy entails a regimented preference 
for a specific antibiotic in a given envi-
ronment over a fixed period, after which 
preference is switched to an alternative 
agent with a similar spectrum of activity. 
The assumption underlying this strate-
gy is that the exposure to each antibio-
tic in the schedule is sufficiently short to 
preclude the emergence of significant 
populations of micro-organisms resi-
stant to any one of them.
The evidence to support this recom-
mendation is sparse and the data are 
conflicting. (15,16) In a cardiac ICU, six 
months of ceftazidime administration 
was followed by six months of cipro-
floxacin administration and a compari-
son was made. (15) Although not true 
cycling (the prior regimen was not reu-
sed, therefore the effect of a full cycle 
was not tested), this study suggested 
that scheduled changes in classes of 
antibiotics may reduce infection with 
resistant AGNB. There was a significant 
reduction in the incidence of pneumo-
nia due to resistant AGNB (4% versus 
0.9% p = 0.013). The non-randomised 
design is a fundamental flaw confirmed 
by the difference in the etiology of the 
causative agents. During ceftazidime 
treatment there was an outbreak of 
intrinsically resistant Serratia (7 pne-
umonias), additionally there were five 
viral and three Aspergillus pneumonias, 
ie. 15 of 41 pneumonias were inappro-
priately treated by ceftazidime. During 
ciprofloxacin treatment there were 22 
pneumonias in total, only one of which 
was viral. The difference in pneumonia 
is no longer significant when comparing 
the appropriately treated pneumonias, 
ie. 26 and 21.
In a neonatal ICU, a monthly rotation 
of gentamicin, piperacillin-tazobactam, 
and ceftazidime was compared with 
unrestricted antibiotic use between 
two geographically separated teams 
(rotation versus control team). (16) In 
total, 10.7% of infants on the rotation 
team versus 7.7% on the control team 
carried resistant AGNB in the throat 
and gut. There was no difference in the 
incidence of infections, morbidity, and 
mortality.
Proponents and antagonists of antibi-
otic cycling agree that there are many 
difficult and complex methodological 
issues, surrounding the use of antibiotic 
cycling.
Factors potentially determining the 
effectiveness of antibiotic cycling inclu-
de endemic rates of carriage with par-
ticular AGNB and their mechanisms of 
antibiotic resistance, the transmission 
dynamics of particular AGNB in a speci-
fic unit, the population dynamics of the 
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unit staff, the composition and duration 
of the antibiotic regimens, compliance 
with antibiotic cycling, and concurrent 
infection control practices to limit tran-
smission of resistant AGNB. There is 
limited information on which to base 
decisions of how long each antibiotic 
regimen should be used and how many 
regimens should be cycled.
Control of transmission of 
resistant micro-organisms 
via hands of carers
The endpoint of traditional infection 
control is the control of infection due to 
the control of transmission of resistant 
micro-organisms via hands of carers. 
The two main manoeuvres are isolation 
(17) and hand washing. (18) A recent 
two-centre prospective crossover study 
from the United Kingdom, demonstra-
ted that placing patients who are trea-
ted in ICU and who carry MRSA or who 
are infected by MRSA in single rooms or 
cohorting them in a multi-bed bay when 
a single room was not available, had no 
effect on transmission of MRSA when 
combined with what the investigators 
term “standard” (17) precautions for all 
patients treated on ICU.
The experts tried to explain this negati-
ve study by the poor adherence to hand 
hygiene, the hand washing compliance 
rate was 21% in the study. (19) A recent 
systematic review of hand washing 
suggests that hand washing does not 
abolish but only reduces transmission 
of potential pathogens by lowering the 
contamination level of hands. (18)
The policy of sole use of parenteral 
antimicrobials has failed to control resi-
stance. Generally, resistance to a new 
antibiotic emerges within two years of 
general use. (20,21) We believe that 
this experience is due to the common 
denominator of ignoring the gut in all 
four manoeuvres of restricted antibiotic 
use, cycling of antibiotics, isolation and 
hand washing. The major source of 
the gut is left intact allowing resistant 
mutants to emerge and to cause supe-
rinfections and subsequent outbre-
aks. There are four long-term studies 
(2 years) evaluating the impact of 
polymyxin/tobramycin on resistance 
amongst AGNB. (22-25)
The resistance data of the long-term 
studies confirm the RCT findings that 
rates of carriage and infection due to 
resistant AGNB in patients receiving 
enteral and parenteral antimicrobials 
are not increased but actually lower 
compared with patients receiving solely 
parenteral antimicrobials.
Most patients who require long-term 
treatment on ICU have overgrowth of 
abnormal flora defined as 105 AGNB 
per ml of saliva and/or per g of faeces. 
Gut overgrowth guarantees increased 
spontaneous mutation, leading to pol-
yclonality and antimicrobial resistance. 
(2) As parenteral antimicrobials gene-
rally fail to eradicate the abnormal carri-
er state in overgrowth concentrations, 
the enteral antimicrobials polymyxin/
tobramycin aiming at converting the 
abnormal carrier state into normal carri-
age, is the essential component of SDD, 
because they eradicate carriage and 
overgrowth of AGNB including resistant 
mutants, maintaining the usefulness of 
parenteral antimicrobials.
Approximately one third of patients requ-
iring treatment on ICU, import resistant 
micro-organisms in their admission 
flora, about one third acquire resistant 
micro-organisms following transmissi-
on via hands of carers, and the last 
third develop de novo resistance due to 
mutation following gut overgrowth.
SDD using enteral polymyxin/tobra-
mycin with or without vancomycin pre-
vents acquisition and de novo develo-
pment in eradicating abnormal flora of 
resistant bacteria present in the admi-
ssion flora.
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